Although AbbVie saw sales rise to $8.31 billion in the fourth quarter, the increase was still a blow to the company’s stock because it came below analysts’ estimate of $8.38 billion for the quarter. In the fourth quarter of 2017, AbbVie had sales of $7.74 billion.
Revenue growth in the fourth quarter was attributed to a 50 percent increase in the company’s global hematologic oncology profile, according to the report.
AbbVie’s stock fell 6 percent Jan. 25 on news of the missed estimate in the fourth quarter.
More articles on pharmacy:
Cancer therapy prices prevent access to treatment, WHO says
Despite controversies, J&J ranks among Fortune’s most-admired companies
Bristol-Myers swings to $1.2B profit in Q4
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
